Argá Medtech SA

Argá Medtech SA is a medical device company based in Epalinges, Switzerland, founded in June 2020.

The company focuses on developing a next-generation non-thermal cardiac ablation system using Pulsed Field Ablation (PFA) technology to treat cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia. With a team of approximately 25 employees, Argá Medtech has raised $70.3 million in funding, including a significant oversubscribed Series B round. The company's proprietary Coherent Sine-Burst ElectroporationTM (CSETM) system utilizes pulsed electrical fields to create irreversible electroporation of cardiomyocytes. This innovative approach minimizes collateral damage to surrounding tissues, enhancing safety and effectiveness compared to traditional thermal methods. The versatile catheter design allows for the treatment of various arrhythmias with a single device, and the system is currently preparing for larger clinical studies to achieve FDA approval after a successful first-in-human study. Argá Medtech aims to improve treatment outcomes for millions affected by cardiac rhythm disorders.